Lawrence A. Kenyon's most recent trade in Outlook Therapeutics Inc was a trade of 5,000 Common Stock done at an average price of $5.7 . Disclosure was reported to the exchange on Sept. 26, 2024.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Outlook Therapeutics Inc | Lawrence A. Kenyon | Director, Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 5.69 per share. | 26 Sep 2024 | 5,000 | 5,946 (0%) | 0% | 5.7 | 28,446 | Common Stock |
| Outlook Therapeutics Inc | Lawrence A. Kenyon | Director, CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Mar 2024 | 12,500 | 12,500 | - | - | Stock Option (Right to Buy) | |
| Outlook Therapeutics Inc | Lawrence A. Kenyon | Director, CEO, Pres, CFO, Treas & Secy | Purchase of securities on an exchange or from another person at price $ 1.83 per share. | 20 Apr 2021 | 10,000 | 18,926 (0%) | 0% | 1.8 | 18,300 | Common Stock |